My Healthcare News & Research — March 14, 2026

A New Cholesterol Guideline Lowers the Targets — and Tells Every Adult to Check Their Lp(a)

On March 13, 2026, the American College of Cardiology and the American Heart Association — joined by eleven other professional organizations — published a new guideline on the management of dyslipidemia, the medical umbrella term for unhealthy blood lipids: high cholesterol, high triglycerides, and elevated lipoprotein(a). It appeared at the same time in the two flagship cardiology journals, Circulation and the Journal of the American College of Cardiology, and it retires the 2018 cholesterol guideline that has shaped how American doctors treat cholesterol for the past eight years.

A guideline is not a single study. It is a panel of experts reading the entire body of evidence and writing down what they now recommend. Because nearly every primary-care doctor and cardiologist in the country leans on these documents, a new one quietly changes the care that tens of millions of people receive. This one makes three notable moves.

What Actually Changed

1. Firmer LDL cholesterol targets. The 2018 guideline leaned mostly on statin intensity and used the LDL number as a threshold for deciding when to add a second drug. The 2026 guideline puts explicit numeric LDL goals back at the center. LDL-C — the harmful particle that drives artery plaque — is now given clear targets:

The phrase the authors return to is “lower for longer” — the idea that keeping LDL low across decades, not just after a heart attack, reduces the lifetime buildup of plaque.

2. A better risk calculator. The guideline replaces the older Pooled Cohort Equations with the AHA’s newer PREVENT calculator. The old tool was found to overestimate a person’s 10-year heart risk by roughly 40–50% in today’s population, which meant some people were told they needed medication when their true risk was lower. PREVENT also folds in kidney function and metabolic health. The new risk bands are: low (under 3%), borderline (3 to under 5%), intermediate (5 to under 10%), and high (10% or more) over ten years.

3. Universal Lp(a) screening — the single biggest change. For the first time, the guideline recommends that every adult have their lipoprotein(a), or “Lp(a),” measured at least once in their lifetime. Lp(a) is a largely inherited particle that raises heart-attack and stroke risk independently of ordinary LDL. Roughly one in five people carries a high level and has no idea. A level at or above 125 nmol/L (about 50 mg/dL) is considered elevated; around 250 nmol/L is linked to at least double the risk. Because Lp(a) is set mostly by your genes, a single test usually tells you your lifetime status.

What It Means for You

For most people the message is simple. If you have never had your Lp(a) measured, this guideline is the reason to ask for it at your next blood draw — it is a one-time, inexpensive test that can explain an unexplained family history of early heart disease. If you already take a statin, the lower LDL targets may prompt your doctor to add a second, well-established medicine — oral ezetimibe or bempedoic acid, or an injectable PCSK9 inhibitor — to push your number down further. And because the new calculator is less alarmist, some lower-risk people may actually be moved off medication they never really needed. The guideline also nudges cholesterol screening earlier, suggesting a first check in children between ages 9 and 11.

Honest Caveats

A few things are worth keeping in perspective:

The Practical Takeaway

Two concrete actions. First, if you are an adult who has never had an Lp(a) test, ask for one — once is enough, and knowing changes how you and your doctor weigh everything else. Second, if you are already being treated for cholesterol, ask what your LDL number is and whether the new, lower target applies to you. The 2026 guideline is, at its heart, an argument that your cholesterol numbers matter earlier and lower than we used to think — so the most useful thing you can do is find out what yours are.

Sources